Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 8/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900840 | 0.82 | VNN1 (0.45) | VNN1DPP4DPP8USP30HSD11B1 | |
| SCHEMBL5901127 | 0.82 | VNN1 (0.45) | VNN1DPP4DPP8USP30HSD11B1 | |
| SCHEMBL2990621 | 0.82 | VNN1 (0.45) | VNN1DPP4DPP8USP30HSD11B1 | |
| SCHEMBL21782989 | 0.80 | USP30 (0.58) | VNN1USP30HSD11B1 | |
| SCHEMBL21464535 | 0.80 | L3MBTL3 (0.50) | USP30L3MBTL3 | |
| SCHEMBL2883536 | 0.80 | L3MBTL3 (0.50) | USP30L3MBTL3 | |
| SCHEMBL2883532 | 0.80 | L3MBTL3 (0.50) | USP30L3MBTL3 | |
| SCHEMBL13939912 | 0.79 | CCR5 (0.44) | VNN1DPP4KCNH2DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3404368 | 0.78 | L3MBTL3 (0.49) | USP30L3MBTL3 | |
| Hydrochloric Acid SCHEMBL3427002 | 0.78 | L3MBTL3 (0.49) | USP30L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885DPP4 1631/4885KCNH2 2224/4885 |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885DPP4 1631/4885KCNH2 2224/4885 |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | VNN1 23/4885DPP4 1631/4885KCNH2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.